There are two specific goals of this project. The first is to characterize prothrombin activation as it occurs during in vitro blood clotting. We will study activation of both Factors ahd platelets and how subsequent prothrombin activation is influenced by these reactions. Human Factor V will be purified from fresh plasma. Thrombin-activated Factor Va (Factor Va) will be added to blood and its effect on prothrombin activation during in vitro clotting measured by our radioimmunoassay for thrombin. We will also make specific antibodies against Factor Va. Those antibodies which cross-react with Factor V will be removed by affinity chromatography. We will develop a radioimmunoassay for Factor Va using the anti-Factor Va antibody. The RIA will be used to study activation of Factor V during blood clotting. We will also determine the effect of the antibodies on thrombin formation. To determine the role of platelets in prothrombin activation, the effects of selectively activating platelets or varying the platelet concentration will be studied. To determine the role of platelet Factor V, platelets from Factor V-deficient patients or normal controls will be added to normal plasma and the effect on thrombin formation determined. These experiments will provide new information on the normal physiology of blood clotting. The second goal of this project is to further characterize the covalent binding of thrombin to platelets and endothelial cells. To obtain information on the functional inportance of the covalent binding of thrombin to endothelial cells, we will determine the relationship of binding to the inhibitory effect of thrombin on the plasminogena activity of endothelium. We will also determine whether binding of (125I) Factor Xa cultured bovine aortic endothelial cells is similar to thrombin binding to these cells. Covalent binding of activated coagulation factors to endothelium may serve as a mechanism for removing them from the circulation. Thrombin binding to endothelial cells will be localized using transmission electron microscopy and anti-thrombin IgG adsorbed to colloidal gold. We will also purify these covalent binding sites for thrombin from conditioned culture media from endothelial cells, and from the supernatant of platelets stimulated to undergo the release reaction. These studies should increase our understanding of the interaction between platelets, blood vessels, and clotting factors, and as a result, clarify the importance of these reactions in clotting.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Stricker, R B; Lewis, B H; Corash, L et al. (1987) Posttransfusion purpura associated with an autoantibody directed against a previously undefined platelet antigen. Blood 69:1458-63
Greenberg, C S; Achyuthan, K E; Borowitz, M J et al. (1987) The transglutaminase in vascular cells and tissues could provide an alternate pathway for fibrin stabilization. Blood 70:702-9
Stricker, R B; Reyes, P T; Corash, L et al. (1987) Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor. J Clin Invest 79:1589-94
Weisberg, L J; Shiu, D T; Conkling, P R et al. (1987) Identification of normal human peripheral blood monocytes and liver as sites of synthesis of coagulation factor XIII a-chain. Blood 70:579-82
Rodgers, G M; Shuman, M A (1987) Enhancement of prothrombin activation on platelets by endothelial cells and mechanism of activation of factor V. Thromb Res 45:145-52
Weisberg, L J; Shiu, D T; Greenberg, C S et al. (1987) Localization of the gene for coagulation factor XIII a-chain to chromosome 6 and identification of sites of synthesis. J Clin Invest 79:649-52
Stricker, R B; Shuman, M A (1986) Quinidine purpura: evidence that glycoprotein V is a target platelet antigen. Blood 67:1377-81
Stricker, R B; Wong, D; Shiu, D T et al. (1986) Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood 68:275-80
Stricker, R B; Wong, D; Saks, S R et al. (1985) Acquired Bernard-Soulier syndrome. Evidence for the role of a 210,000-molecular weight protein in the interaction of platelets with von Willebrand factor. J Clin Invest 76:1274-8
Greenberg, C S; Miraglia, C C; Rickles, F R et al. (1985) Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. J Clin Invest 75:1463-70

Showing the most recent 10 out of 13 publications